Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVI-4020 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVI-4020 Injection | DRUG | - |
Inclusion Criteria: * Adult males 18 years to 64 years of age; * Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) * Signed and dated written informed consent form; and * Willing to partici...
AVI-4020 is an investigational small molecule being developed for West Nile Virus. It is currently in Phase 1 clinical development, meaning it has not been approved and is still being studied for safety and pharmacokinetics in humans.
AVI-4020 is being developed by Sarepta Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker SRPT. The company is conducting clinical research on this drug candidate for West Nile Virus.
AVI-4020 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
AVI-4020 has been studied in one completed Phase 1 clinical trial, NCT00387283, titled "Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020." The trial enrolled 14 healthy male volunteers aged 18 years and older in the United States.
AVI-4020 is the primary name for this investigational drug candidate. No alternative names have been reported for this compound in clinical development.